Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

NVO
Novo-Nordisk A/S
stock NYSE ADR

At Close
May 16, 2025 3:59:30 PM EDT
64.38USD-2.676%(-1.77)19,012,644
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 16, 2025 9:28:30 AM EDT
64.08USD-3.129%(-2.07)1,516,498
After-hours
May 16, 2025 4:58:30 PM EDT
64.32USD-0.093%(-0.06)31,848
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:14AM EST  Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that Novos exploration team will provide a comprehensive update on exploration activities in Western Australia and Victoria at the following upcoming webinar:   GlobeNewswire Inc
Jan 28, 2022
10:19AM EST  Novo Resources Exploration Update   GlobeNewswire Inc
Jan 25, 2022
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2022   Benzinga
08:35AM EST  Liberum Downgrades Novo Nordisk to Sell   Benzinga
Jan 21, 2022
09:26AM EST  High-Grade Assay Results at the Parnell-Vulture Trend   GlobeNewswire Inc
Jan 14, 2022
11:17AM EST  UPDATE: Novo Nordisk Says Settlement Contains No Admission Of Liability, No Payment Will Be Made By Co.   Benzinga
11:15AM EST  Novo Nordisk Settles Securities Suit In Denmark   Benzinga
08:48AM EST  FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report   Benzinga
08:30AM EST  Nullagine Gold Project Production Update   GlobeNewswire Inc
Jan 7, 2022
08:30AM EST  2022 A Year of Growth for Novo Resources   GlobeNewswire Inc
Jan 4, 2022
10:43AM EST  Novo Drops 4%, Downtick Continues   RTTNews
Dec 31, 2021
01:00PM EST  If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today   Benzinga
Dec 25, 2021
09:38PM EST  Dicerna Pharmaceuticals Inc. (DRNA) said that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired on December 24, 2021.   RTTNews
Dec 21, 2021
07:49AM EST  Commencement of Phase 2 Mechanical Sorter Trials at Nullagine Gold   GlobeNewswire Inc
Dec 20, 2021
12:34PM EST  President Biden Tweets 'Right now, there's a kid out there whose family can't afford her insulin because it costs $1,000 per month. The Build Back Better Act would cap their monthly insulin costs at $35. I'm committed as ever to getting it done for them.'   Benzinga
11:58AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021   Benzinga
10:46AM EST  This Is What Whales Are Betting On Novo Nordisk   Benzinga
08:42AM EST  JP Morgan Downgrades Novo Nordisk to Neutral   Benzinga
Dec 17, 2021
03:33PM EST  Novo Nordisk shares are trading lower. The company announced supply challenges for Wegovy in the US but said it will not impact FY21 guidance.   Benzinga
12:21PM EST  Novo Nordisk Announces Supply Challenges For Wegovy In U.S.; Says Will Not Impact Previously Communicated FY21 Guidance; Says Will Provide FY22 Guidance In Feb. 2022   Benzinga
Dec 16, 2021
08:48AM EST  Novo/GBM JV Commences Inaugural Malmsbury Gold Project Diamond   GlobeNewswire Inc
Dec 14, 2021
05:55PM EST  & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA   PR Newswire
Dec 13, 2021
08:47AM EST  Mining Review Delivers Optimized Five-Year Plan   GlobeNewswire Inc
06:41AM EST  Novo Nordisk Invests More than DKK 17B ($2.6B) in Expansion of Manufacturing Facilities in Kalundborg, Denmark   Benzinga
Nov 30, 2021
08:06AM EST  Novo Identifies Ni-Cu Targets at Southcourt, Andover Intrusion,   GlobeNewswire Inc
Nov 26, 2021
01:38AM EST  Danish pharmaceutical company Novo Nordisk A/S (NVO) Friday said it has received the results from the Volume Based Procurement or VBP tender for insulin in China.   RTTNews
01:22AM EST  Novo Nordisk Gets Results From Volume Based Procurement Tender For Insulin In China   RTTNews
Nov 19, 2021
11:15PM EST  & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNA   PR Newswire
08:49AM EST  Novo Commences 15,000 m RC Drilling Program at the Parnell-Vulture   GlobeNewswire Inc
Nov 18, 2021
02:36PM EST  Mid-Afternoon Market Update: Dow Falls 75 Points; Dicerna Pharmaceuticals Shares Spike Higher   Benzinga
12:35PM EST  Mid-Day Market Update: Macy's Surges After Q3 Results; Amtech Systems Shares Plunge   Benzinga
10:21AM EST  Mid-Morning Market Update: Markets Down; Kohl's Earnings Top Expectations   Benzinga
10:04AM EST  Dicerna Shares Spike On Agreement To Be Acquired By Novo   RTTNews
07:02AM EST  Novo Nordisk To Acquire Dicerna For $38.25/Share In Cash   Benzinga
Nov 16, 2021
02:32PM EST  What Are 10 Of The Most Popular Dividend Stocks?   Benzinga
Nov 12, 2021
08:19AM EST  EMA Backs Approval Of Novo Nordisk's Ozempic 2mg Dose For Diabetes   Benzinga
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
06:10AM EST  Novo Nordisk Reports Ozempic 2.0mg Recommended For Approval For Treatment Of Type 2 Diabetes By European Medicines Agency   Benzinga
06:10AM EST  Novo Nordisk (NVO) announced the European Medicines Agency's CHMP has adopted a positive opinion recommending a label extension for the existing marketing authorisation for Ozempic, to introduce a new dose of 2.0 mg. Ozempic is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes.   RTTNews
06:01AM EST  Novo Nordisk: EMA Recommends Label Extension For Ozempic 2.0 Mg For Type 2 Diabetes   RTTNews
Nov 11, 2021
02:14PM EST  European Authorities Recommend Approval Of Wegovy For Obesity   Benzinga
10:58AM EST  Novo Nordisk Shares Volatile Amid News Co. Sees Approval Of Its Wegovy Candidate For Treatment Of Obesity In Europe In 2 Months   Benzinga
10:57AM EST  Novo Nordisk Shares Volatile Amid Report Co. Sees Approval Of Its Wegovy Candidate For Treatment Of Obesity In Europe In 2 Months   Benzinga
Nov 10, 2021
08:13AM EST  Mechanical Sorter Construction Complete Ahead of Phase 2 Trials at   GlobeNewswire Inc
Nov 5, 2021
09:44AM EDT  Novo Nordisk; Highlights Presentation Of Results From STEP 5 Phase 3b Trial; Says Wegovy 'demonstrated significant and sustained weight loss' In Two-Year Study   Benzinga
08:46AM EDT  Wegovy(tm) demonstrated significant and sustained weight loss in two-year study   PR Newswire
07:58AM EDT  Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) wishes to advise that operations have resumed at its Golden Eagle processing facility (Golden Eagle Mill).   GlobeNewswire Inc
Nov 3, 2021
09:11AM EDT  Novo Nordisk Reported Net Profit of $1.89B vs $1.8B Est; CEO Said Demand for Obesity Drug Wegovy Exceeded Expectations; Co Increased Share Buyback by $311M   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
02:58AM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) reported that its net profit for the first nine months of 2021 rose 12% to 36.87 billion Danish kroner from last year's 32.82 billion kroner, with earning per share improving to 15.98 kroner from 14.00 kroner in the previous year.   RTTNews
02:38AM EDT  Novo Nordisk 9-month Sales Up 8% In Danish Kroner And By 13% At CER To DKK 102.5 Bln   RTTNews
Nov 1, 2021
08:00AM EDT  Nullagine Gold Project Update   GlobeNewswire Inc
Oct 29, 2021
02:29PM EDT  Novo Nordisk Boosts FY21 Outlook After Solid Q3 Sales   Benzinga
10:48AM EDT  Novo Nordisk Sees FY21 Sales Growth 12%-15%   Benzinga
10:47AM EDT  Novo Nordisk Raises Guidance   Benzinga
Oct 21, 2021
08:22AM EDT  Near-Mine High-Grade Mineralization Confirmed 3 km from Golden   GlobeNewswire Inc
Oct 12, 2021
07:20AM EDT  Nullagine Gold Project Production Update   GlobeNewswire Inc
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 27, 2021
03:57PM EDT  Novo Nordisk Settles Insulin Pricing Lawsuit For $100M   Benzinga
08:02AM EDT  High Grade Gold Intersected in First Drill Program at Talga Talga   GlobeNewswire Inc
01:16AM EDT  BIOCORP, a French medical devices company, announced Monday an agreement with Danish pharmaceutical company Novo Nordisk A/S (NVO) for the development and distribution of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.   RTTNews
12:50AM EDT  BIOCORP, NOVO NORDISK Sign Partnership For Development Of Mallya Smart Add-on Device For Novo Nordisk FlexTouch Pen   RTTNews
Sep 24, 2021
10:07AM EDT  Novo Nordisk Reports Settlement Of US Securities Class Action Litigation, Will Pay $100M   Benzinga
Sep 8, 2021
08:00AM EDT  Accelerated Near-Mine Exploration Program Underway at   GlobeNewswire Inc
Aug 20, 2021
02:34PM EDT  House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices   Benzinga
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 6, 2021
09:09AM EDT  Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that senior management will provide an operational and exploration update from the Nullagine gold project and the Pilbara region in Western Australia at the following upcoming webinars:   GlobeNewswire Inc
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
11:05AM EDT  BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations   Benzinga
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
08:00AM EDT  Record Monthly Production From Nullagine Gold Project   GlobeNewswire Inc
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
12:10PM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) Wednesday reported first-half net profit of 24.75 billion Danish krone or 10.71 krone per share, up from last year's 22.52 billion krone or 9.58 krone per share.   RTTNews
10:54AM EDT  Novo Nordisk H1 Operating Profit Decreases By 1% In Danish Kroner   RTTNews
10:30AM EDT  Novo Nordisk Sees FY21 Sales Growth 10%-13%   Benzinga
10:29AM EDT  Novo Nordisk Q2 2021 EBIT DKK14,779B   Benzinga
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 12, 2021
02:31PM EDT  Mid-Afternoon Market Update: Dow Surges Over 100 Points; State Auto Financial Shares Jump   Benzinga
12:24PM EDT  Mid-Day Market Update: Crude Oil Down 1%; Celldex Therapeutics Shares Spike Higher   Benzinga
10:27AM EDT  Mid-Morning Market Update: Markets Mostly Higher; Novo Nordisk To Acquire Prothena's ATTR Amyloidosis Program   Benzinga
08:30AM EDT  Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B   Benzinga
07:27AM EDT  Novo Nordisk Buys Prothena's Clinical Stage Antibody PRX004 And Broader ATTR Amyloidosis Programme   RTTNews
07:05AM EDT  Prothena And Novo Nordisk Announce Definitive Purchase Agreement Under Which Novo Nordisk Acquired Prothena's PRX004 And Broader ATTR Amyloidosis Program; Prothena Eligible To Receive $1.2B In Sales Milestones Including $100M In Upfront/Near-Term Payments   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
09:29AM EDT  Quarterly Operational Update; Increased Production From Beatons Creek   GlobeNewswire Inc
Jun 29, 2021
08:51AM EDT  Walmart, Novo Nordisk Unveil Own Low-Cost Brand Insulin   Benzinga
08:39AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jun. 29, 2021: SOFI, PLTR, CLSK, XHB, NVO   Benzinga
Jun 28, 2021
06:49AM EDT  Novo Nordisk's Higher Dose Of Semaglutide Trumped 1-mg Predecessor On Blood Sugar, Weight Reduction   Benzinga
Jun 22, 2021
09:33PM EDT  Novo Announces Results of Annual General Meeting of Shareholders   GlobeNewswire Inc
Jun 18, 2021
08:51AM EDT  Novo Resources Corp. (Novo or the Company) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) today announced details of the Companys upcoming annual general meeting (the Meeting) scheduled for 4:00 p.m. PDT on Tuesday, June 22, 2021, and investor presentation to be held subsequent to the Meeting at 4:30 p.m. PDT.   GlobeNewswire Inc
Jun 16, 2021
10:00AM EDT  A Look Into Novo Nordisk's Price Over Earnings   Benzinga
09:30AM EDT  Novo Nordisk, Lumen Bioscience Collaborate For Oral Biologics For Cardiometabolic Diseases   Benzinga
08:11AM EDT  Lumen Bioscience And Novo Nordisk Enter Research Collaboration To Explore Novel Strategies To Deliver Oral Biologics For Cardiometabolic Disease; Financial Details Not Disclosed   Benzinga
Jun 11, 2021
09:03AM EDT  Not for Distribution to United States Newswire Services or for dissemination in the United States   GlobeNewswire Inc
08:05AM EDT  The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts   Benzinga
Jun 10, 2021
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
Jun 8, 2021
09:48AM EDT  Nullagine Gold Project Update   GlobeNewswire Inc
Jun 7, 2021
08:15AM EDT  Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity   Benzinga
05:16AM EDT  Novo Nordisk CFO Said Expects Approval of Semaglutide for Weight Management Treatment in the EU in December; Said Wegovy Could Eat into Sales of its Existing Obesity Drug Saxenda in the U.S.   Benzinga
Jun 4, 2021
05:02PM EDT  The U.S. Food and Drug Administration on Friday approved Wegovy, a higher-dose version of Novo Nordisk's (NVO) diabetes drug semaglutide, for chronic weight management in adults with obesity.   RTTNews
03:32PM EDT  FDA Approves Novo Nordisk's Wegovy For Chronic Weight Mgmt.   Benzinga
Jun 3, 2021
09:27AM EDT  Novo Resources Corp. (Novo or the Company) (TSX: NVO & NVO.WT; OTCQX: NSRPF) is pleased to provide an update on its current A$12 million exploration program for the remainder of 2021. The program focuses on two primary objectives:   GlobeNewswire Inc
Jun 1, 2021
08:14AM EDT  Novo Resources Corp. (Novo or the Company) (TSX: NVO & NVO.WT; OTCQX: NSRPF) reports that its annual general meeting (the Meeting) has been scheduled for June 22, 2021 at 4 pm PDT.   GlobeNewswire Inc
May 28, 2021
12:04PM EDT  Novo Nordisk Resubmits Semaglutide 2mg For Type 2 Diabetes In US   Benzinga
10:47AM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) said Friday that it has resubmitted a label expansion application to the US Food and Drug Administration for the existing marketing authorization for Ozempic or semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg.   RTTNews
10:20AM EDT  Novo Nordisk Says Resubmitted Once-Weekly Semaglutide 2 mg For Treatment Of Type-2 Diabetes For US Regulatory Approval   Benzinga
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 18, 2021
08:41AM EDT  Novo Secures Access to PhotonAssay Services by Executing Agreement   GlobeNewswire Inc
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 17, 2021
12:36PM EDT  Novo Nordisk Says Ziltivekimab Reduced Inflammatory Biomarkers Associated With Atherosclerosis In People With Chronic Kidney Disease In Phase 2 Trial   Benzinga
10:13AM EDT  Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
09:33AM EDT  Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis   Benzinga
08:30AM EDT  Novo Completes Malmsbury Option Exercise with GBM Resources Limited   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
05:59AM EDT  Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage temperature conditions, the U.S. Food and Drug Administration said.   RTTNews
May 10, 2021
11:26AM EDT  Stocks That Hit 52-Week Highs On Monday   Benzinga
May 5, 2021
07:24AM EDT  Novo Nordisk's Q1 Sales Buoyed By GLP-1 Products, Lifts FY21 Guidance   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
01:59AM EDT  Novo Nordisk (NVO) reported that its first-quarter net profit rose to 12.62 billion Danish Kroner or 5.45 Kroner per share from 11.90 billion Kroner or 5.05 Kroner per share in the previous year.   RTTNews
01:34AM EDT  Novo Nordisk Q1 Sales Remained Unchanged In Danish Kroner And Up 7% At CER To DKK 33.8 Bln   RTTNews
Apr 21, 2021
01:53PM EDT  Novo Nordisk To Start Phase 3   Benzinga
10:27AM EDT  Novo Nordisk Announced Decision To Enter Phase 3A Development In Obesity With Oral Semaglutide 50mg, Says Intends To Initiate Pivotal Phase 3a Program With ~1K People With Obesity, Overweight With Comorbidities   Benzinga
10:17AM EDT  Novo Nordisk (NVO) said that it has decided to enter phase 3a development in obesity with oral semaglutide 50 mg.   RTTNews
Apr 9, 2021
08:16AM EDT  Novo Reports Amendment of Sprott Credit Facility   GlobeNewswire Inc
Mar 31, 2021
09:38AM EDT  Preliminary Economic Assessment - Beatons Creek Conglomerate Gold   GlobeNewswire Inc
Mar 23, 2021
08:51AM EDT  Novo Provides Further Update on Partial Sale of Blue Spec Project   GlobeNewswire Inc
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
07:27AM EDT  FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application   Benzinga
01:31AM EDT  AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA   RTTNews
Mar 22, 2021
10:34PM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) said Monday that the US Food and Drug Administration issued a Refusal to File letter covering the label expansion application for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes which was filed on 20 January 2021.   RTTNews
05:50PM EDT  Novo Nordisk Believes Already Completed Clinical Trial Program For Semaglutide Will Be Sufficient For Approval Of Label Expansion Application   Benzinga
05:50PM EDT  UPDATE: Novo Nordisk Says FDA Has Requested Added Info Related To Semaglutide, Including Data Related To Proposed New Manufacturing Site   Benzinga
05:49PM EDT  UPDATE: Novo Nordisk Sees Resubmitting Application for Semaglutide 2.0 mg To FDA During Q2'21   Benzinga
05:49PM EDT  Novo Nordisk Reports Received Refusal To File Letter For Once-Weekly Semaglutide 2.0 mg for Treatment Of Type 2 Diabetes   Benzinga
08:25AM EDT  Novo Exercises Option Over Kalamazoo Resources   GlobeNewswire Inc
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
07:47AM EDT  Gilead Sciences, Inc. (GILD) and Novo Nordisk A/S (NOVO B) Thursday said the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis or NASH, a chronic and progressive liver disease that causes fat accumulation and inflammation in the liver that impairs liver function.   RTTNews
06:57AM EDT  Gilead, Novo Nordisk To Test Triple Combo Therapy In New NASH Study   Benzinga
05:03AM EDT  Gilead And Novo Nordisk Expand Clinical Collaboration In Non-alcoholic Steatohepatitis   RTTNews
Mar 15, 2021
09:31AM EDT  Novo Nordisk : Data From STEP Trial Evaluating Effect Of Semaglutide 2.4 Mg In People With Obesity To Be Presented   RTTNews
09:25AM EDT  Novo Nordisk Reports Results From 3 Trials From Pivotal STEP Phase 3 Clinical Development Program Of Semaglutide 2.4 mg Will Be Shared At ENDO Meeting Mar. 20-23   Benzinga
09:24AM EDT  Data from STEP clinical trial program evaluating effect of semaglutide 2.4 mg   PR Newswire
Mar 4, 2021
11:40AM EST  Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study   Benzinga
Feb 25, 2021
05:28AM EST  Novo Nordisk Invests DKK 500M in Expanding Tablet Production Facilities in Denmark   Benzinga
Feb 5, 2021
09:02AM EST  TMX Group Equity Financing Statistics - January 2021   PR Newswire
Feb 3, 2021
08:37AM EST  Novo Nordisk: Q4 Earnings Insights   Benzinga
07:50AM EST  Novo Nordisk Shares Gain On Fourth Quarter Earnings Beat, Stock Repurchase Program   Benzinga
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
05:15AM EST  Novo Nordisk Reported Net Profit Increased by 8% in 2020; Sees FY Sales Growth Of 5%-9% In Local Currencies; Announced New Share Repurchase Program   Benzinga
04:00AM EST  Earnings Scheduled For February 3, 2021   Benzinga
01:56AM EST  Danish pharmaceutical company Novo Nordisk A/S (NVO) reported Wednesday that its fiscal 2020 net profit increased 8 percent to 42.14 billion Danish kroner from last year's 38.95 billion kroner.   RTTNews
01:34AM EST  Novo Nordisk 2020 Sales Increase 4% In Danish Kroner And By 7% At CER To DKK 126.9 Bln   RTTNews
Jan 20, 2021
10:09AM EST  Novo Nordisk Files For Regulatory Approval In U.S> Of Once-Weekly Semaglutide 2.0 MG For Treatment Of Type 2 Diabetes   Benzinga
Jan 19, 2021
10:27AM EST  Senate Finance Committee Ranking Member Wyden Says Wants To See Fresh Investigation Of Big Pharmaceutical 'Price Gouging Schemes' On Insulin   Benzinga
Jan 15, 2021
11:51AM EST  Novo Provides Update From Malmsbury Project in Victoria, Australia   GlobeNewswire Inc
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021   Benzinga
07:38AM EST  Deutsche Bank Initiates Coverage On Novo Nordisk with Buy Rating   Benzinga
Jan 13, 2021
08:37AM EST  Novo Resources Corp. (Novo or the Company) (TSX: NVO & NVO.WT; OTCQX: NSRPF) is pleased to announce that Mr. Michael Spreadborough has accepted an invitation to join its board of directors.   GlobeNewswire Inc
Jan 5, 2021
07:33AM EST  Dicerna Announces Novo Nordisk's Nomination Of First Candidate For Development Under RNAi Discovery And Development Agreement And Additional Milestone Achievement   Benzinga
Jan 4, 2021
09:21AM EST  Novo Nordisk Announces Extension Of Its COVID-19 Patient Assistance Program Until June 30, 2021   RTTNews
09:15AM EST  Novo Nordisk Extends COVID-19 Patient Assistance Program   Benzinga
09:14AM EST  Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people   PR Newswire
Dec 30, 2020
05:34PM EST  Novo Receives Final Approval to Graduate to Toronto Stock Exchange   GlobeNewswire Inc
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
06:52AM EST  Danish pharmaceutical company Novo Nordisk A/S (NVO) said Tuesday it has submitted a label extension application to the European Medicines Agency or EMA for the existing marketing authorisation for Ozempic to introduce a new dose of 2.0 mg.   RTTNews
06:36AM EST  Novo Nordisk Files For EU Regulatory Approval Of Once-weekly Semaglutide 2.0 Mg For Type 2 Diabetes   RTTNews
06:14AM EST  Novo Nordisk Files For EU Regulatory Approval Of Once-Weekly Semaglutide 2.0 Mg For The Treatment Of Type 2 Diabetes   Benzinga
Dec 18, 2020
08:23AM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to announce that its Annual General Meeting of shareholders was held in Vancouver, British Columbia, Canada on December 17, 2020 at which all resolutions were passed, being:   GlobeNewswire Inc
05:15AM EST  Novo Nordisk Files for EU Regulatory Approval of Once-weekly Semaglutide 2.4 Mg for Weight Management   Benzinga
03:07AM EST  Danish pharmaceutical company Novo Nordisk A/S (NVO) Friday announced the submission of a Marketing Authorisation Application to the European Medicines Agency or EMA for subcutaneous semaglutide 2.4 mg, a once-weekly glucagon-like peptide-1 (GLP-1) analogue for weight management.   RTTNews
02:20AM EST  Novo Nordisk Files For EU Regulatory Approval Of Semaglutide 2.4 Mg For Weight Management   RTTNews
Dec 17, 2020
05:34PM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the TSX) to graduate from the TSX Venture Exchange (the TSXV) and list its common shares and certain common share purchase warrants (the Warrants) on the TSX.   GlobeNewswire Inc
10:18AM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to provide an operational update from its Beatons Creek gold project (Beatons Creek) and Nullagine processing facility (Golden Eagle Mill).   GlobeNewswire Inc
05:25AM EST  Maersk Enters Partnership with Novo Nordisk on Global Cold Chain Logistics for Transporting Pharmaceuticals   Benzinga
Dec 16, 2020
08:39AM EST  Novo and Sumitomo Complete Earn-In Over Kangan Project at Egina   GlobeNewswire Inc
08:23AM EST  Novo Nordisk (NVO) said Wednesday that it plans to enter phase 3 development in Alzheimer's disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide.   RTTNews
08:13AM EST  Novo Nordisk To Enter Phase 3 Development In Alzheimer's Disease With 14 Mg Oral Semaglutide   RTTNews
08:10AM EST  Novo Nordisk To Enter Phase 3 Development In Alzheimer's Disease With Oral Semaglutide; Decision To Enter Phase 3 Development In Alzheimer's Disease With 14 Mg Oral Semaglutide, A Once-daily Oral Formulation Of Long-acting GLP-1 Analogue Semaglutide   Benzinga
Dec 15, 2020
04:00PM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) today announced details of the Companys upcoming investor presentation to be held subsequent to the Companys annual general meeting (the Meeting) on December 17, 2020. The presentation will begin at 4:30 p.m. PST and will be accessible through a live presentation link (details provided below).   GlobeNewswire Inc
09:34AM EST  Novo Identifies Numerous Oxide Targets for Follow Up in 2021 at   GlobeNewswire Inc
Dec 8, 2020
04:05PM EST  Novo Nordisk Completes Acquisition of Emisphere Technologies for   GlobeNewswire Inc
09:16AM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to announce it has taken delivery of its Steinert KSS mechanical sorter and provides an operational update from its Beatons Creek gold project (Beatons Creek) and Nullagine processing facility (Golden Eagle Mill).   GlobeNewswire Inc
Dec 4, 2020
09:34PM EST  FDA approves Saxenda(r) for the treatment of obesity in adolescents aged 12-17   PR Newswire
07:30AM EST  Novo Nordisk Files For FDA Regulatory Approval Of Once-Weekly Semaglutide 2.4 Mg For Weight Management   Benzinga
Nov 25, 2020
08:57AM EST  Novo Provides Update on Partial Sale of Blue Spec Project   GlobeNewswire Inc
Nov 19, 2020
04:59PM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) reports that its annual general meeting (the Meeting) has been scheduled for December 17, 2020 at 4 pm PST.   GlobeNewswire Inc
Nov 18, 2020
08:00AM EST  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to provide a further operational update from its Beatons Creek gold project (Beatons Creek) and Nullagine processing facility (Golden Eagle Mill).   GlobeNewswire Inc
Nov 17, 2020
09:39AM EST  Novo Nordisk Says SUSTAIN FORTE Trial Achieved Its Primary Endpoint   RTTNews
09:29AM EST  Novo Nordisk Reports Headline Results From SUSTAIN FORTE Trial For Type-2 Diabetes Treatment   Benzinga
Nov 16, 2020
08:23AM EST  Aeterna Zentaris Amends License Agreement With Novo Nordisk For Commercialization And Development Of Macimorelin; Co. To Receive 5M Upfront Payment   Benzinga
Nov 12, 2020
12:33PM EST  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation   GlobeNewswire Inc
Nov 9, 2020
01:46PM EST  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Emisphere Technologies, Inc. (Other OTC: EMIS) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Novo Nordisk A/S (NYSE: NVO).   GlobeNewswire Inc
Nov 6, 2020
09:10AM EST  (EMIS) Alert: Johnson Fistel Investigates Proposed Sale of Emisphere; Are   PR Newswire
05:49AM EST  Novo Nordisk A/S (NVO) has agreed to acquire Emisphere Technologies Inc., a drug delivery company with proprietary technologies that enable oral formulations of therapeutics. The acquisition provides Novo Nordisk full ownership of the Eligen SNAC technology, which has been used under a licence agreement to develop the first oral biologic, Rybelsus.   RTTNews
05:12AM EST  Novo Nordisk acquires Emisphere Technologies and Obtains Ownership of the Eligen SNAC Oral Delivery Technology for $1.8B   Benzinga
Nov 5, 2020
10:05AM EST  Novo Nordisk Reports Results Of Phase 3a Trial Showed Semaglutide 2.4 mg Once-Weekly Subcutaneous As Adjunct To Intensive Behavorial Therapy Showed Significantly More Body Weight Loss vs Placebo Plus IBT   Benzinga
08:17AM EST  AstraZeneca Misses Q3 Earnings Consensus, Expects COVID-19 Vaccine Trial Results This Year   Benzinga
Nov 3, 2020
03:00PM EST  Novo Nordisk Purchases B Shares Worth 2.913M Danish Krone, Transaction Price Is 413.35 Krone Per Share, Transaction Is Part Of Share Repurchase Program Up To A Total Of 17B Krone   Benzinga
Oct 30, 2020
08:00AM EDT  Novo Provides Second Operational Update From Beatons Creek   GlobeNewswire Inc
04:07AM EDT  Earnings Scheduled For October 30, 2020   Benzinga
02:51AM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) reported Friday that its third-quarter net profit edged up 1 percent to 10.30 billion Danish kroner from last year's 10.19 billion kroner. Earnings per share/ADR grew 3 percent to 4.42 kroner from 4.29 kroner last year.   RTTNews
02:32AM EDT  Novo Nordisk 9-month Sales Up 6% In Danish Kroner And By 7% At CER To DKK 94.8 Bln   RTTNews
Oct 29, 2020
07:51AM EDT  Field Trial Preparatory Testwork at Steinert Perth Recovers   GlobeNewswire Inc
Oct 28, 2020
08:11AM EDT  UPDATE: Keros Therapeutics Says 'As a result of the termination of the Collaboration Agreement, the Company will regain worldwide rights to all ligand traps selected under the Collaboration Agreement'   Benzinga
08:10AM EDT  Keros Therapeutics On Oct 26, Got Notice From Novo Nordisk That It Has Elected To Terminate Research Collaboration, Exclusive License Agreement; Novo Nordisk's Decision To Terminate Collaboration Agreement Was Due To Strategic And Business Reasons   Benzinga
Oct 15, 2020
07:56AM EDT  Novo Provides Operational Update From Beatons Creek and Millennium   GlobeNewswire Inc
Oct 11, 2020
06:35PM EDT  IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week   Benzinga
Oct 9, 2020
10:03AM EDT  FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs   Benzinga
Oct 8, 2020
10:19PM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) said that it raised its full-year sales and operating profit outlook at constant exchange rates.   RTTNews
12:45PM EDT  Novo Nordisk Sees FY20 Sales Growth 5-8% Year Over Year   Benzinga
12:45PM EDT  UPDATE: Novo Nordisk Reports Q3 Sales, Operating Profit Up 7%   Benzinga
12:42PM EDT  Novo Nordisk Raises Sales, Operating Profit For 2020   Benzinga
Oct 6, 2020
10:07AM EDT  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO; OTCQX: NSRPF) is pleased to announce that mapping and surface rock sampling indicate the possibility of considerable extensions of the Beatons Creek conglomerate gold system.   GlobeNewswire Inc
Sep 29, 2020
05:14PM EDT  Novo Initiates Due Diligence Under Kalamazoo Option   GlobeNewswire Inc
Sep 24, 2020
09:01AM EDT  Novo Exercises Option Over GBM Resources   GlobeNewswire Inc
Sep 22, 2020
09:20AM EDT  Novo Nordisk Announces Results From Three Phase 2 Clinical Trials For Insulin Icodec   RTTNews
08:51AM EDT  Novo Nordisk Shares Quiet; Co. Announces Results From 3 Phase 2 Trials For Insulin Icodec, Primary Endpoint Showed Insulin Icodec With Loading Dose Showed Significantly Greater Time In Range vs Insulin Glargine U100   Benzinga
08:24AM EDT  Novo Acquires Option Over Kalamazoo Resources   GlobeNewswire Inc
Sep 21, 2020
08:38AM EDT  Novo Resources Corp. (Novo or the Company) (TSX-V: NVO; OTCQX: NSRPF) is pleased to announce that it has signed a binding terms sheet (the Terms Sheet) with ASX-listed Calidus Resources Limited (Calidus) to sell a portion of the Companys Blue Spec project for gross cash consideration of A$19.5 million (approximately C$18.6 million) (the Cash Consideration) (the Transaction).   GlobeNewswire Inc
Sep 15, 2020
07:44AM EDT  Novo Reaches First Completion Milestone With Creasy Group, Expands   GlobeNewswire Inc
Sep 14, 2020
08:11AM EDT  Novo Settles Millennium Minerals Limiteds Debt   GlobeNewswire Inc
Sep 3, 2020
02:04PM EDT  Why Morgan Stanley Is Buying The Dip In Eli Lilly   Benzinga
Aug 18, 2020
05:28AM EDT  Evotec and Novo Nordisk Form Strategic Alliance to Develop Novel Therapies for Kidney Diseases; Evotec tol Receive Undisclosed Upfront Payment, Research Funding and Milestone Potential of More Than 150M Per Product. Tiered Royalties on Net Sales   Benzinga
02:03AM EDT  Evotec, Novo Nordisk Enter Collaboration In Chronic Kidney   RTTNews
01:45AM EDT  Evotec, Novo Nordisk Announce Strategic Collaboration   RTTNews
Aug 13, 2020
05:19AM EDT  Novo Nordisk Resumes Phase 3 Clinical Trials Investigating Concizumab (Anti-tfpi Mab) in Haemophilia A and B With or Without Inhibitors Following Pausing of Trials in March 2020 Due to Occurrence of Non-fatal Thrombotic Events in Three Patients Enrolled in Ongoing Phase 3 Programme   Benzinga
Aug 6, 2020
08:53AM EDT  IIROC Trading Resumption - NVO   PR Newswire
02:22AM EDT  Danish pharmaceutical company Novo Nordisk A/S (NVO) reported Thursday that its second-quarter net profit grew 11 percent to 10.63 billion Danish kroner from last year's 9.60 billion kroner.   RTTNews
01:36AM EDT  Novo Nordisk H1 Sales Up 8% In Danish Kroner And By 7% At CER To DKK 63.9 Bln   RTTNews
Aug 4, 2020
08:02AM EDT  IIROC Trading Halt - NVO   PR Newswire
Jul 31, 2020
09:50AM EDT  Novo Files Egina Technical Report and Satisfies Bellary Dome   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC